157 related articles for article (PubMed ID: 15077996)
1. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
2. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2007 Nov; 30(5):415-21. PubMed ID: 17768034
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
Piddock LJ; Jin YF
J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O
Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey.
Decousser JW; Allouch PY; Courvalin P; Leclercq R;
Int J Antimicrob Agents; 2002 Sep; 20(3):186-95. PubMed ID: 12385697
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
9. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
10. Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone.
Drago L; Mattina R; Legnani D; Romano CL; Vianello E; Ricci C; De Vecchi E
Int J Immunopathol Pharmacol; 2011; 24(4):1027-35. PubMed ID: 22230408
[TBL] [Abstract][Full Text] [Related]
11. Influence of human ascitic fluid on the in vitro antibacterial activity of moxifloxacin.
Miglioli PA; Cappellari G; Cavallaro A; Cardaioli C; Sossai P; Fille M; Allerberger F
J Chemother; 2005 Aug; 17(4):401-3. PubMed ID: 16167519
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of moxifloxacin against local bacterial isolates.
Ling ML; Tan PL
Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
[TBL] [Abstract][Full Text] [Related]
13. Comparative bactericidal activity of fluoroquinolones against clinical isolates resistant to fluoroquinolones.
Drago L; De Vecchi E; Nicola L; Valli M; Marchetti F; Gismondo MR
J Chemother; 2003 Apr; 15(2):118-23. PubMed ID: 12797386
[TBL] [Abstract][Full Text] [Related]
14. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
15. In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.
Kowalski RP; Kowalski TA; Shanks RM; Romanowski EG; Karenchak LM; Mah FS
Cornea; 2013 Jun; 32(6):830-4. PubMed ID: 23132444
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal properties of moxifloxacin and post-antibiotic effect.
Boswell FJ; Andrews JM; Wise R; Dalhoff A
J Antimicrob Chemother; 1999 May; 43 Suppl B():43-9. PubMed ID: 10382875
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.
Boswell FJ; Andrews JM; Wise R
Antimicrob Agents Chemother; 1997 Jun; 41(6):1377-9. PubMed ID: 9174203
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
20. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
